Clinical trial · Observational
Master Framework For Relapse or Refractory Acute Myeloid Leukemia
Master Framework For Relapse or Refractory Acute Myeloid Leukemia- IMPACT STREAM - A Prospective Observational Study of Treatment Outcomes
NCT06459024CI-TRIAL-00122057IMPACT STREAMrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an observational (non-interventional), prospective, cohort study that will collects data from patients diagnosed with relapsed or refractory acute myeloid leukemia afferent to the participanting clinical sites
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
| Acute Myeloid Leukemia Refractory | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Registration into the STREAM platform | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients with relapsed or refractory acute myeloid leukemia
- description
- All patients with relapsed or refractory acute myeloid leukemia
- interventionNames
- Other: Registration into the STREAM platform
Primary outcomes (1)
- measure
- The primary endpoint is to determine the overall survival of R/R AML patients
- timeFrame
- 8 years
- description
- Overall survival is defined as the time from R/R diagnosis to death due to any cause.
Secondary outcomes (7)
- measure
- Remission rate
- timeFrame
- 8 years
- description
- Response is defined according to ELN 2022 criteria. Rates of CR, CRi, CRh and overall response (CR+CRi+CRh) as best response will be considered
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 6 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with AML diagnosis according to WHO2022 or ICC2022 * Treatment failure (i.e. relapse, refractory or progression, including MRD) according to ELN2022 criteria * Participant or his/her legal representative is willing and able to give informed consent for participation in the study Exclusion Criteria: * Patients included in clinical trials may be enrolled except where otherwise specified in the experimental protocol.
References
Publications (0)
Data not yet available
No reference posted for this study.